Hepatocellular Carcinoma: Symptoms, Diagnosis, and Radiologic Insights

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, often arising in the setting of chronic liver disease. Recognizing hepatocellular carcinoma symptoms early is crucial for improving patient outcomes. This article provides a comprehensive overview of the clinical presentation, diagnostic modalities including hepatocellular carcinoma radiology, and the hepatocellular carcinoma ICD 10 coding that guides clinical documentation.

Understanding Hepatocellular Carcinoma Symptoms

Patients with HCC may remain asymptomatic in the early stages, making screening especially important in at-risk populations such as those with cirrhosis or chronic hepatitis B or C. When symptoms do appear, they can be nonspecific and may include:

• Abdominal pain or discomfort in the upper right quadrant
• Unexplained weight loss and anorexia
• Jaundice (yellowing of the skin and eyes)
• Swelling in the abdomen (ascites) or legs (edema)
• Fatigue and general malaise
• Nausea and vomiting
• Easy bruising or bleeding due to impaired liver function

As the tumor progresses, patients may develop more specific manifestations such as a palpable liver mass, fever, or endocrine abnormalities. It is important to note that hepatocellular carcinoma symptoms can overlap with those of chronic liver disease, so a high index of suspicion is necessary.

Diagnosis of Hepatocellular Carcinoma

A definitive diagnosis of HCC involves a combination of clinical assessment, laboratory tests, and imaging studies. The diagnostic algorithm typically begins with non-invasive imaging, especially in patients with cirrhosis, where characteristic imaging features can confirm HCC without the need for biopsy.

Laboratory Tests

Serum biomarkers such as alpha-fetoprotein (AFP) are often elevated in HCC, though they are not sufficiently sensitive or specific for diagnosis alone. Elevated liver enzymes, bilirubin, and abnormal coagulation profiles may also be present due to underlying liver disease.

Imaging Studies

Hepatocellular carcinoma radiology plays a central role in diagnosis. The key imaging modalities include:

• Ultrasound (US): First-line screening tool; HCC appears as a hypoechoic or hyperechoic mass with arterial hypervascularization.
• Contrast-enhanced computed tomography (CT): Shows arterial enhancement with washout in the portal venous or delayed phase—hallmark of HCC.
• Magnetic resonance imaging (MRI): Provides superior soft tissue contrast and can characterize lesions using hepatobiliary contrast agents.
• Angiography: Occasionally used for preoperative planning or embolization.

The Liver Imaging Reporting and Data System (LI-RADS) standardizes the interpretation and reporting of these findings, assigning scores from LR-1 (benign) to LR-5 (definite HCC). A lesion with LI-RADS 5 classification is considered diagnostic for HCC in high-risk patients.

The Role of Radiology in Hepatocellular Carcinoma Diagnosis

As mentioned, hepatocellular carcinoma radiology is the cornerstone of diagnosis. Each imaging modality offers unique advantages. Ultrasound is widely available and inexpensive, making it ideal for surveillance. CT is excellent for staging and detection of extrahepatic spread. MRI, especially with liver-specific contrast agents, can help characterize small lesions and distinguish HCC from other liver masses such as hemangiomas or metastases.

Dynamic contrast-enhanced imaging captures the hypervascular nature of HCC. The typical pattern is arterial phase hyperenhancement followed by venous or delayed phase washout. This pattern is so specific that it is considered diagnostic in the appropriate clinical context. LI-RADS scoring incorporates these features along with lesion size, threshold growth, and ancillary features like hepatobiliary phase hypointensity.

Advanced techniques such as diffusion-weighted imaging (DWI) and elastography add functional information about cellularity and stiffness, respectively. These can aid in prognosis and treatment planning.

ICD-10 Coding for Hepatocellular Carcinoma

Accurate documentation using the hepatocellular carcinoma ICD 10 code is essential for medical records, billing, and research. The primary code is C22.0 for liver cell carcinoma. Additional codes may be used to specify related conditions such as hepatitis B (B18.0 or B18.1), cirrhosis (K74.60), or alcohol-related liver disease (K70.3).

Proper code assignment requires careful review of the medical record to identify the primary malignancy and any associated risk factors. The ICD-10 classification system also includes codes for personal history of liver cancer (Z85.050). Clinicians should be aware of these codes to ensure comprehensive documentation.

Conclusion

Early recognition of hepatocellular carcinoma symptoms and timely diagnostic workup are critical for improving survival. Hepatocellular carcinoma diagnosis relies heavily on advanced imaging techniques, with hepatocellular carcinoma radiology providing non-invasive, highly accurate identification of tumors. Familiarity with hepatocellular carcinoma ICD 10 coding supports clinical practice and data collection. Multidisciplinary collaboration between hepatologists, radiologists, and pathologists ensures optimal patient management.